Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 8-K (Current Report)
Date of Report: December 18, 2025
Event: Entry into a Material Definitive Agreement for a registered direct offering and concurrent private placement.
Key Financial Metrics
Capital Raised: Approximately $2.5 million in aggregate gross proceeds.
Use of Proceeds: Working capital and general corporate purposes.
Placement Fees: 7% of aggregate gross proceeds paid to Aegis Capital Corp.
Financial Performance: The filing does not provide revenue, profit, cash flow, margin, or debt metrics.
Material Changes and Transaction Details
- Securities Issued:
- 1,430,502 shares of Common Stock at $1.295 per share.
- 500,000 Pre-Funded Warrants at $1.29499 per warrant (exercisable at $0.00001).
- Private Placement Warrants exercisable for up to 1,930,502 shares at $1.4245 per share.
- Ownership Limitations: Warrants contain limitations preventing exercise if the holder would beneficially own more than 4.99% (or 9.99% upon election) of outstanding Common Stock.
- Registration Rights: Company agreed to file a resale registration statement within 30 days of closing.
Guidance, Outlook, and Risks
Management Commentary: The Company intends to utilize net proceeds for working capital and general corporate purposes. No specific operational guidance or future earnings outlook is provided in this filing.
Risks and Contingencies: The filing notes the issuance of unregistered securities (Private Placement Warrants) under Section 4(a)(2) of the Securities Act. Dilution risk exists due to the issuance of new shares and warrants.
Investor Verification Checklist
- Verify the final closing date and net proceeds after deducting the 7% placement fee and other expenses.
- Confirm the total number of outstanding shares post-offering to assess immediate dilution impact.
- Review the "shelf" registration statement (File No. 333-288039) for prior capital raising history.
- Monitor the filing of the Resale Registration Statement within the required 30-day window.
- Check for any subsequent press releases regarding the utilization of the $2.5 million in proceeds.